WA
TMO icon

Wambolt & Associates’s Thermo Fisher Scientific TMO Stock Holding History

Wambolt & Associates’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$809K Sell
1,919
-248
-11% -$104K 0.27% 95
2025
Q1 		$1.05M Sell
2,167
-50
-2% -$27.1K 0.36% 82
2024
Q4 		$1.15M Buy
2,217
+2
+0.1% +$1.1K 0.37% 81
2024
Q3 		$1.36M Sell
2,215
-38
-2% -$22.5K 0.37% 81
2024
Q2 		$1.22M Sell
2,253
-8
-0.4% -$4.58K 0.35% 80
2024
Q1 		$1.31M Sell
2,261
-3
-0.1% -$1.68K 0.39% 81
2023
Q4 		$1.2M Sell
2,264
-13
-0.6% -$6.29K 0.39% 86
2023
Q3 		$1.13M Buy
2,277
+54
+2% +$28.8K 0.41% 84
2023
Q2 		$1.16M Buy
2,223
+2
+0.1% +$1.08K 0.41% 88
2023
Q1 		$1.27M Sell
2,221
-50
-2% -$28.2K 0.45% 79
2022
Q4 		$1.25M Sell
2,271
-6
-0.3% -$3.18K 0.48% 78
2022
Q3 		$1.16M Sell
2,277
-11
-0.5% -$6.16K 0.49% 78
2022
Q2 		$1.24M Sell
2,288
-43
-2% -$23.7K 0.5% 66
2022
Q1 		$1.38M Buy
2,331
+12
+0.5% +$6.89K 0.5% 72
2021
Q4 		$1.55M Sell
2,319
-12
-0.5% -$7.49K 0.56% 63
2021
Q3 		$1.33M Buy
2,331
+46
+2% +$25.2K 0.54% 66
2021
Q2 		$1.16M Buy
2,285
+25
+1% +$11.8K 0.49% 72
2021
Q1 		$1.03M Sell
2,260
-20
-0.9% -$9.55K 0.54% 69
2020
Q4 		$1.06M Hold
2,280
– – 0.63% 54
2020
Q3 		$1.01M Sell
2,280
-81
-3% -$33.5K 0.75% 41
2020
Q2 		$855K Sell
2,361
-2
-0.1% -$670 0.67% 48
2020
Q1 		$670K Sell
2,363
-105
-4% -$33.1K 0.69% 45
2019
Q4 		$802K Sell
2,468
-25
-1% -$7.58K 0.61% 53
2019
Q3 		$726K Hold
2,493
– – 0.6% 55
2019
Q2 		$732K Sell
2,493
-10
-0.4% -$2.75K 0.62% 51
2019
Q1 		$695K Buy
2,503
+1,103
+79% +$274K 0.63% 46
2018
Q4 		$313K Buy
+1,400
New +$328K 0.35% 100

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wambolt & Associates's TMO Position: Q2 2025 in Review

Wambolt & Associates reduced its Thermo Fisher Scientific (TMO) stake by 11% in Q2 2025, selling an estimated $104K and leaving 1,919 shares worth $809K. The position accounts for 0.27% of the portfolio, ranked #95.

Wambolt & Associates first reported a position in TMO in Q4 2018 and has held it in 27 quarters since. The position peaked at $1.55M in Q4 2021. 2,454 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

  • Wambolt & Associates held 1,919 shares of Thermo Fisher Scientific worth $809K as of Q2 2025.
  • Wambolt & Associates sold 248 Thermo Fisher Scientific shares in Q2 2025, an estimated $104K.
  • Thermo Fisher Scientific made up 0.27% of Wambolt & Associates's portfolio in Q2 2025, its #95 holding.
  • Wambolt & Associates first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 27 quarters since.
  • Wambolt & Associates's Thermo Fisher Scientific position peaked at $1.55M in Q4 2021.
  • 2,454 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on Wambolt & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.